BREAKING

SiTime Corporation Jumps 5.2% in Broad Rally 1 day ago Guidewire Software Drops 5.9% Amid Sector-Wide Selling 1 day ago Korn Ferry Drops 5.5% in Broad Selloff 1 day ago Commvault Systems (CVLT) Jumps 9.8% to $88.47 1 day ago Nexstar Media Group Stock Jumps 5% Amid Sector-Wide Rally 1 day ago TransMedics Group Shares Jump 5.0% 1 day ago Rambus Inc. Jumps 6.3% 2 days ago Clear Secure, Inc. Drops 6.1% in Broad Selloff 2 days ago DigitalOcean Holdings, Inc. Drops 7.2% in Broad Selloff 2 days ago CleanSpark, Inc. (CLSK) Jumps 5.2% to $10.39 2 days ago SiTime Corporation Jumps 5.2% in Broad Rally 1 day ago Guidewire Software Drops 5.9% Amid Sector-Wide Selling 1 day ago Korn Ferry Drops 5.5% in Broad Selloff 1 day ago Commvault Systems (CVLT) Jumps 9.8% to $88.47 1 day ago Nexstar Media Group Stock Jumps 5% Amid Sector-Wide Rally 1 day ago TransMedics Group Shares Jump 5.0% 1 day ago Rambus Inc. Jumps 6.3% 2 days ago Clear Secure, Inc. Drops 6.1% in Broad Selloff 2 days ago DigitalOcean Holdings, Inc. Drops 7.2% in Broad Selloff 2 days ago CleanSpark, Inc. (CLSK) Jumps 5.2% to $10.39 2 days ago

ADVERTISEMENT

RE

REGN

All REGN Content

42 articles, transcripts, and reports

Regeneron Pharmaceuticals Inc (REGN) Barclays 28th Annual Global Healthcare Conference

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Corporate Conference

March 5, 20261 min read

Regeneron Pharmaceuticals Inc (REGN) Dupixent (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release

February 27, 20261 min read

Regeneron Pharmaceuticals Inc (REGN) Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release

February 26, 20261 min read

Regeneron Pharmaceuticals Inc (REGN) Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release

February 24, 20261 min read

ADVERTISEMENT

Regeneron Pharmaceuticals Inc (REGN) Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release

February 19, 20261 min read

Regeneron Pharmaceuticals Inc (REGN) Q4 2025 Earnings Call

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q4 2025 Earnings Conference

February 16, 20261 min read

Regeneron Pharmaceuticals Inc (REGN) Leerink Partners 2026 Global Healthcare Conference

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Corporate Conference

February 11, 20261 min read

Regeneron Pharmaceuticals Inc (REGN) TD Cowen 46th Annual Health Care Conference

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Corporate Conference

February 11, 20261 min read

ADVERTISEMENT

Regeneron Pharmaceuticals Inc (REGN) Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release

February 10, 20261 min read

Regeneron Pharmaceuticals Inc (REGN) Q4 2025 Earnings Call Transcript

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q4 2025 Earnings Call dated Jan. 30, 2026 Corporate Participants: Ryan Crowe — Senior Vice President of Investor Relations &…

February 2, 202650 min read